RevaTis
BioTech/Drugs - N/A, N/A, US
RevaTis Employees
RevaTis Details
RevaTis and University of Liège have developed and patented a specific procedure for the collection, production and storage of autologous muscle-derived mesenchymal stem cells (MdMSC) for immediate therapeutic use or storage for further processing. RevaTis technology is minimally invasive and offers benefits for generating a large number of autologous stem cells. Our sustainable avantages:- patents granted for obtaining pluripotent stem cells by a minimally invasive method for human and veterinary medicine- GMP production in aseptic isolator- Authorization for the production of batches in veterinary and human medicine for clinical studies or research- Accredited stem cell tissue-banksOur Market:The global market for stem cell treatments in animals has a growing rate annual average of 37.27% between 2017 and 2025 and will reach more than 200.000.000 €. In 2017, the global market for equine-level cell therapy was estimated at one third of the global market, In Human Medicine, RevaTis will focuse on the segment "Stem Cell Research and Services. This segment was $ 1,300 million in 2017 to arrive at a size estimate of market of $ 2,400 million in 2022.Our customers: In Vet Medicine, after the approval by agencies, our potential customer are the veterinarians. For Human Application, our markets include partners involved in - R&D Programs on Regenerative Medicine and Cell Therapy - Tissu engineering and 3D-Bio-Printing - Organ on a chip technology.In other words, all companies or Resarch Centers looking for a sourcing of large quantities of MSCs easily to transer in clinic.
RevaTis Technologies
Email Providers
Gmail
Domain Name Services
Cloudflare DNS
Fonts
Google Font API
Other
Google Maps
Hosting
CloudFlare Hosting